Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H1 2016

  • ID: 3746947
  • Report
  • 713 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AB Science SA
  • Boehringer Ingelheim GmbH
  • F. Hoffmann-La Roche Ltd.
  • Incyte Corporation
  • Merck & Co., Inc.
  • OXiGENE, Inc.
  • MORE
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H1 2016

Summary

‘Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H1 2016’, provides an overview of the Head And Neck Cancer Squamous Cell Carcinoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Head And Neck Cancer Squamous Cell Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Head And Neck Cancer Squamous Cell Carcinoma
- The report reviews pipeline therapeutics for Head And Neck Cancer Squamous Cell Carcinoma by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Head And Neck Cancer Squamous Cell Carcinoma therapeutics and enlists all their major and minor projects
- The report assesses Head And Neck Cancer Squamous Cell Carcinoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Head And Neck Cancer Squamous Cell Carcinoma

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Head And Neck Cancer Squamous Cell Carcinoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Head And Neck Cancer Squamous Cell Carcinoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AB Science SA
  • Boehringer Ingelheim GmbH
  • F. Hoffmann-La Roche Ltd.
  • Incyte Corporation
  • Merck & Co., Inc.
  • OXiGENE, Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Head And Neck Cancer Squamous Cell Carcinoma Overview

Therapeutics Development

Pipeline Products for Head And Neck Cancer Squamous Cell Carcinoma - Overview

Pipeline Products for Head And Neck Cancer Squamous Cell Carcinoma - Comparative Analysis

Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics under Development by Companies

Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics under Investigation by Universities/Institutes

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Unknown Stage Products

Head And Neck Cancer Squamous Cell Carcinoma - Products under Development by Companies

Head And Neck Cancer Squamous Cell Carcinoma - Products under Investigation by Universities/Institutes

Head And Neck Cancer Squamous Cell Carcinoma - Companies Involved in Therapeutics Development

AB Science SA

AbbVie Inc.

Acceleron Pharma, Inc.

Advaxis, Inc.

Altor BioScience Corporation

Amgen Inc.

AstraZeneca Plc

AVEO Pharmaceuticals, Inc.

Bayer AG

Bionovis SA

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

CEL-SCI Corporation

Cellceutix Corporation

Celldex Therapeutics, Inc.

Celltrion, Inc.

Centrose LLC

Critical Outcome Technologies Inc.

Daiichi Sankyo Company, Limited

Debiopharm International SA

Eisai Co., Ltd.

Eli Lilly and Company

Etubics Corporation

F. Hoffmann-La Roche Ltd.

G&E Herbal Biotechnology Co., Ltd.

Genexine, Inc.

Genmab A/S

GlaxoSmithKline Plc

Gliknik, Inc.

Glycotope GmbH

Hanmi Pharmaceuticals, Co. Ltd.

Horizon Pharma Plc

Immunomedics, Inc.

Immunovative Therapies, Ltd.

Incyte Corporation

Innate Pharma S.A.

Inovio Pharmaceuticals, Inc.

IRX Therapeutics, Inc.

Kolltan Pharmaceuticals, Inc.

Laboratoires Pierre Fabre SA

Loxo Oncology, Inc.

Mabion SA

MacroGenics, Inc.

Marsala Biotech Inc.

MedImmune, LLC

Merck & Co., Inc.

Merck KGaA

Merrimack Pharmaceuticals, Inc.

Millennium Pharmaceuticals, Inc.

Mirati Therapeutics Inc.

Molecular Partners AG

Molplex Ltd.

Novartis AG

Oncobiologics, Inc.

Oncolytics Biotech Inc.

Onconova Therapeutics, Inc.

OncoSec Medical Incorporated

Ono Pharmaceutical Co., Ltd.

OXiGENE, Inc.

Panacea Biotec Limited

PCI Biotech Holding ASA

Pfizer Inc.

Sanofi

Shanghai Henlius Biotech Co., Ltd.

Shenzen SiBiono GeneTech Co., Ltd.

Shionogi & Co., Ltd.

Sillajen Biotherapeutics

Symphogen A/S

Synta Pharmaceuticals Corp.

Takara Bio Inc.

Threshold Pharmaceuticals, Inc.

UbiVac, LLC

VasGene Therapeutics, Inc.

VentiRx Pharmaceuticals, Inc.

Virttu Biologics Limited

Viventia Bio Inc.

Vyriad

Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

ABBV-221 - Drug Profile

AdIL-24 - Drug Profile

afatinib dimaleate - Drug Profile

alisertib - Drug Profile

AlloVax - Drug Profile

alpelisib - Drug Profile

ALT-803 - Drug Profile

AMG-319 - Drug Profile

Antibodies to Inhibit FRMD4A for Oncology - Drug Profile

Antisense Oligonucleotide to Target EGFR for Head and Neck Cancer Squamous Cell Carcinoma - Drug Profile

AV-203 - Drug Profile

avelumab - Drug Profile

axalimogene filolisbac - Drug Profile

AZD-5069 - Drug Profile

AZD-6738 - Drug Profile

AZD-9150 - Drug Profile

bleomycin sulfate - Drug Profile

BMS-986016 - Drug Profile

BNV-003 - Drug Profile

buparlisib hydrochloride - Drug Profile

cabazitaxel - Drug Profile

capmatinib - Drug Profile

Cellular Immunotherapy for Oncology - Drug Profile

Cellular Immunotherapy to Target EGFR for Head and Neck Cancer Squamous Cell Carcinoma - Drug Profile

cetuximab - Drug Profile

cetuximab biobetter - Drug Profile

cetuximab biosimilar - Drug Profile

cetuximab biosimilar - Drug Profile

cetuximab biosimilar - Drug Profile

cetuximab biosimilar - Drug Profile

cetuximab biosimilar - Drug Profile

cetuximab biosimilar - Drug Profile

copanlisib hydrochloride - Drug Profile

COTI-2 - Drug Profile

dalantercept - Drug Profile

Debio-1143 - Drug Profile

depatuxizumab - Drug Profile

DNA IL-12 - Drug Profile

DPV-001 - Drug Profile

DTP-348 - Drug Profile

durvalumab - Drug Profile

durvalumab + tremelimumab - Drug Profile

E-10A - Drug Profile

E-7046 - Drug Profile

EBC-46 - Drug Profile

EDC-2 - Drug Profile

elgemtumab - Drug Profile

enoblituzumab - Drug Profile

epacadostat - Drug Profile

ETBX-041 - Drug Profile

everolimus - Drug Profile

ficlatuzumab - Drug Profile

futuximab - Drug Profile

ganetespib - Drug Profile

gedatolisib - Drug Profile

Gene Therapy to Activate p53 for Head and Neck Squamous Cell Carcinoma - Drug Profile

Gene Therapy to Activate p53 for Oncology - Drug Profile

GL-0817 - Drug Profile

golvatinib tartrate - Drug Profile

GS-10 - Drug Profile

GSK-2636771 - Drug Profile

GSK-2849330 - Drug Profile

GSK-3174998 - Drug Profile

GX-051 - Drug Profile

HF-10 - Drug Profile

HSV-1716 - Drug Profile

IC-1001 - Drug Profile

INCB-50465 - Drug Profile

INO-3106 - Drug Profile

INO-3112 - Drug Profile

interferon gamma-1b - Drug Profile

IRX-2 - Drug Profile

JX-929 - Drug Profile

KGP-94 - Drug Profile

KM-3174 - Drug Profile

KTN-3379 - Drug Profile

lenvatinib mesylate - Drug Profile

Leukocyte Interleukin - Drug Profile

LGK-974 - Drug Profile

lirilumab - Drug Profile

LN-145 - Drug Profile

LOXO-101 - Drug Profile

lumretuzumab - Drug Profile

masitinib - Drug Profile

MEDI-0562 - Drug Profile

merestinib - Drug Profile

MGCD-265 - Drug Profile

MGD-009 - Drug Profile

monalizumab - Drug Profile

Monoclonal Antibodies to Antagonize Frizzled Receptors for Breast Cancer and Head And Neck Cancer Squamous Cell Carcinoma - Drug Profile

Monoclonal Antibody to Target CD147 for Pancreatic Adenocarcinoma and Head and Neck Cancer Squamous Cell Carcinoma - Drug Profile

motolimod - Drug Profile

MP-0250 - Drug Profile

nilotinib - Drug Profile

nimotuzumab - Drug Profile

nivolumab - Drug Profile

NP-001 - Drug Profile

olaparib - Drug Profile

Oncolytic Virus to Activate IFN-b for Hepatocellular Carcinoma and Head And Neck Cancer Squamous Cell Carcinoma - Drug Profile

Oncolytic Virus to Target CD46 for Recurrent Squamous Cell Carcinoma Head and Neck Cancer - Drug Profile

palbociclib - Drug Profile

panitumumab - Drug Profile

patritumab - Drug Profile

pelareorep - Drug Profile

pembrolizumab - Drug Profile

PF-04518600 - Drug Profile

PF-06801591 - Drug Profile

poziotinib - Drug Profile

prexasertib - Drug Profile

Recombinant Peptide to Target EGFR for Oncology - Drug Profile

Recombinant Protein for Oncology - Drug Profile

rigosertib sodium - Drug Profile

S-488210 - Drug Profile

sacituzumab - Drug Profile

SB-01 - Drug Profile

seribantumab - Drug Profile

SF-1126 - Drug Profile

Small Molecules for Head and Neck Cancer Squamous Cell Carcinoma - Drug Profile

Small Molecules to Inhibit 16S rRNA for Head And Neck Cancer Squamous Cell Carcinoma and Oral Cancer - Drug Profile

Small Molecules to Inhibit CREB Protein for Head And Neck Cancer Squamous Cell Carcinoma - Drug Profile

Small Molecules to Inhibit IL-6 for Head and Neck Squamous Cell Carcinoma - Drug Profile

solarise - Drug Profile

Synthetic Peptide for Head and Neck Cancer Squamous Cell Carcinoma - Drug Profile

tarloxotinib bromide - Drug Profile

tisotumab vedotin - Drug Profile

trametinib dimethyl sulfoxide + uprosertib - Drug Profile

UBS-109 - Drug Profile

urelumab - Drug Profile

utomilumab - Drug Profile

varlilumab - Drug Profile

Vas-01 - Drug Profile

VB-4847 - Drug Profile

vinflunine ditartrate - Drug Profile

Head And Neck Cancer Squamous Cell Carcinoma - Recent Pipeline Updates

Head And Neck Cancer Squamous Cell Carcinoma - Dormant Projects

Head And Neck Cancer Squamous Cell Carcinoma - Discontinued Products

Head And Neck Cancer Squamous Cell Carcinoma - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Head And Neck Cancer Squamous Cell Carcinoma, H1 2016

Number of Products under Development for Head And Neck Cancer Squamous Cell Carcinoma - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Development by Companies, H1 2016 (Contd..1)

Number of Products under Development by Companies, H1 2016 (Contd..2)

Number of Products under Development by Companies, H1 2016 (Contd..3)

Number of Products under Development by Companies, H1 2016 (Contd..4)

Number of Products under Development by Companies, H1 2016 (Contd..5)

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Comparative Analysis by Unknown Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016 (Contd..1)

Products under Development by Companies, H1 2016 (Contd..2)

Products under Development by Companies, H1 2016 (Contd..3)

Products under Development by Companies, H1 2016 (Contd..4)

Products under Development by Companies, H1 2016 (Contd..5)

Products under Development by Companies, H1 2016 (Contd..6)

Products under Development by Companies, H1 2016 (Contd..7)

Products under Development by Companies, H1 2016 (Contd..8)

Products under Investigation by Universities/Institutes, H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by AB Science SA, H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by AbbVie Inc., H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Acceleron Pharma, Inc., H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Advaxis, Inc., H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Altor BioScience Corporation, H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Amgen Inc., H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by AstraZeneca Plc, H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by AVEO Pharmaceuticals, Inc., H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Bayer AG, H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Bionovis SA, H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Boehringer Ingelheim GmbH, H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Bristol-Myers Squibb Company, H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by CEL-SCI Corporation, H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Cellceutix Corporation, H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Celldex Therapeutics, Inc., H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Celltrion, Inc., H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Centrose LLC, H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Critical Outcome Technologies Inc., H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Daiichi Sankyo Company, Limited, H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Debiopharm International SA , H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Eisai Co., Ltd., H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Eli Lilly and Company, H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Etubics Corporation, H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by G&E Herbal Biotechnology Co., Ltd., H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Genexine, Inc., H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Genmab A/S, H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by GlaxoSmithKline Plc, H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Gliknik, Inc., H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Glycotope GmbH, H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Horizon Pharma Plc, H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Immunomedics, Inc., H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Immunovative Therapies, Ltd., H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Incyte Corporation, H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Innate Pharma S.A., H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Inovio Pharmaceuticals, Inc., H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by IRX Therapeutics, Inc., H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Kolltan Pharmaceuticals, Inc., H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Laboratoires Pierre Fabre SA, H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Loxo Oncology, Inc., H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Mabion SA, H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by MacroGenics, Inc., H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Marsala Biotech Inc., H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by MedImmune, LLC, H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Merck & Co., Inc., H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Merck KGaA, H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Mirati Therapeutics Inc., H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Molecular Partners AG, H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Molplex Ltd., H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Novartis AG, H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Oncobiologics, Inc., H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Oncolytics Biotech Inc., H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Onconova Therapeutics, Inc., H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by OncoSec Medical Incorporated, H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by OXiGENE, Inc., H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Panacea Biotec Limited, H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by PCI Biotech Holding ASA, H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Pfizer Inc., H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Sanofi, H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Shanghai Henlius Biotech Co., Ltd., H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Shenzen SiBiono GeneTech Co., Ltd., H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Shionogi & Co., Ltd., H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Sillajen Biotherapeutics, H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Symphogen A/S, H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Synta Pharmaceuticals Corp., H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Takara Bio Inc., H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Threshold Pharmaceuticals, Inc., H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by UbiVac, LLC, H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by VasGene Therapeutics, Inc., H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by VentiRx Pharmaceuticals, Inc., H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Virttu Biologics Limited, H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Viventia Bio Inc., H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Vyriad, H1 2016

Assessment by Monotherapy Products, H1 2016

Assessment by Combination Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Head And Neck Cancer Squamous Cell Carcinoma Therapeutics - Recent Pipeline Updates, H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Dormant Projects, H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Dormant Projects (Contd..1), H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Dormant Projects (Contd..2), H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Dormant Projects (Contd..3), H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Discontinued Products, H1 2016

Head And Neck Cancer Squamous Cell Carcinoma - Discontinued Products (Contd..1), H1 2016

List of Figures

Number of Products under Development for Head And Neck Cancer Squamous Cell Carcinoma, H1 2016

Number of Products under Development for Head And Neck Cancer Squamous Cell Carcinoma - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy Products, H1 2016

Assessment by Combination Products, H1 2016

Number of Products by Top 10 Targets, H1 2016

Number of Products by Stage and Top 10 Targets, H1 2016

Number of Products by Top 10 Mechanism of Actions, H1 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016

Number of Products by Top 10 Routes of Administration, H1 2016

Number of Products by Stage and Top 10 Routes of Administration, H1 2016

Number of Products by Top 10 Molecule Types, H1 2016

Number of Products by Stage and Top 10 Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
AB Science SA
AbbVie Inc.
Acceleron Pharma, Inc.
Advaxis, Inc.
Altor BioScience Corporation
Amgen Inc.
AstraZeneca Plc
AVEO Pharmaceuticals, Inc.
Bayer AG
Bionovis SA
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
CEL-SCI Corporation
Cellceutix Corporation
Celldex Therapeutics, Inc.
Celltrion, Inc.
Centrose LLC
Critical Outcome Technologies Inc.
Daiichi Sankyo Company, Limited
Debiopharm International SA
Eisai Co., Ltd.
Eli Lilly and Company
Etubics Corporation
F. Hoffmann-La Roche Ltd.
G&E Herbal Biotechnology Co., Ltd.
Genexine, Inc.
Genmab A/S
GlaxoSmithKline Plc
Gliknik, Inc.
Glycotope GmbH
Hanmi Pharmaceuticals, Co. Ltd.
Horizon Pharma Plc
Immunomedics, Inc.
Immunovative Therapies, Ltd.
Incyte Corporation
Innate Pharma S.A.
Inovio Pharmaceuticals, Inc.
IRX Therapeutics, Inc.
Kolltan Pharmaceuticals, Inc.
Laboratoires Pierre Fabre SA
Loxo Oncology, Inc.
Mabion SA
MacroGenics, Inc.
Marsala Biotech Inc.
MedImmune, LLC
Merck & Co., Inc.
Merck KGaA
Merrimack Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc.
Mirati Therapeutics Inc.
Molecular Partners AG
Molplex Ltd.
Novartis AG
Oncobiologics, Inc.
Oncolytics Biotech Inc.
Onconova Therapeutics, Inc.
OncoSec Medical Incorporated
Ono Pharmaceutical Co., Ltd.
OXiGENE, Inc.
Panacea Biotec Limited
PCI Biotech Holding ASA
Pfizer Inc.
Sanofi
Shanghai Henlius Biotech Co., Ltd.
Shenzen SiBiono GeneTech Co., Ltd.
Shionogi & Co., Ltd.
Sillajen Biotherapeutics
Symphogen A/S
Synta Pharmaceuticals Corp.
Takara Bio Inc.
Threshold Pharmaceuticals, Inc.
UbiVac, LLC
VasGene Therapeutics, Inc.
VentiRx Pharmaceuticals, Inc.
Virttu Biologics Limited
Viventia Bio Inc.
Vyriad
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll